GeneDx Holdings Corp.

GeneDx Holdings Corp. traces its public-market origins to Casdin & Churchill Acquisition Corp. (Nasdaq: CMLF), a healthcare-focused SPAC that completed its initial public offering in 2020. The blank-check vehicle was sponsored by a joint venture of Casdin Capital and Churchill Capital, two investment firms with deep roots in life sciences and healthcare investing. The SPAC completed its business combination with GeneDx, a genomic diagnostics company spun out of OPKO Health, in April 2022; post-merger, the combined entity began trading on Nasdaq under the ticker WGS, focused on whole-genome sequencing and rare disease diagnostics. This June 2023 8-K reflects ongoing reporting obligations of the post-combination company. Visit SpacDesk and sign up for full data on this and every active SPAC transaction.